Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

Phase 2

Active, not recruiting

Conditions: Heart Failure

Interventions: Drug: REGN5381
Drug: Matching Placebo

First Posted Date: 2022-04-29

Last Posted Date: 2025-02-21

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT05353166

Locations: 🇲🇩
ARENSIA Exploratory Medicine at the Republican Clinical Hospital, Chișinău, Moldova, Republic of

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Phase 3

Recruiting

Conditions: Melanoma

Interventions: Drug: Fianlimab
Drug: Pembrolizumab
Drug: Cemiplimab
Drug: Placebo

First Posted Date: 2022-04-29

Last Posted Date: 2024-10-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 1535

Registration Number: NCT05352672

Locations: 🇺🇸
Atlantic Health System - Morristown Medical Center, Morristown, New Jersey, United States
🇦🇷
Fundacion Cenit para la Investigacion en Neurociencias, Buenos Aires, Argentina
🇦🇷
DIABAID - Instituto de Asistencia Integral en Diabetes, Buenos Aires, Argentina

and more 216 locations

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Other: Non-Interventional

First Posted Date: 2022-04-21

Last Posted Date: 2023-10-19

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 595

Registration Number: NCT05338892

Locations: 🇬🇧
Regeneron Research Facility, Nottingham, United Kingdom

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma

Completed

Conditions: Relapsed/Refractory Follicular Lymphoma

Interventions: Other: Non-Interventional

First Posted Date: 2022-04-21

Last Posted Date: 2023-10-18

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 247

Registration Number: NCT05338879

Locations: 🇬🇧
Regeneron Research Facility, Nottingham, United Kingdom

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: REGN15160 (SC)
Drug: REGN15160 (IV)
Drug: Matching Placebo (IV)
Drug: Matching Placebo (SC)

First Posted Date: 2022-03-24

Last Posted Date: 2023-02-23

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 104

Registration Number: NCT05293678

Locations: 🇧🇪
Regeneron Study Site, Leuven, Belgium

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN9035
Drug: REGN5381
Other: Placebo

First Posted Date: 2022-03-22

Last Posted Date: 2024-04-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 93

Registration Number: NCT05291546

Locations: 🇧🇪
Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven, Belgium
🇩🇪
Charite Research Organisation GmbH, Berlin, Germany

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Metastatic Solid Tumor

Interventions: Drug: 89Zr˗DFO˗REGN5054
Drug: cemiplimab

First Posted Date: 2022-02-28

Last Posted Date: 2025-02-12

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT05259709

Locations: 🇳🇱
UMC Groningen, Groningen, Netherlands

Compassionate Use of Pozelimab

First Posted Date: 2022-02-09

Last Posted Date: 2024-11-08

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT05232110

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Completed

Conditions: Moderate-to-severe Atopic Dermatitis

Interventions: Drug: dupilumab

First Posted Date: 2022-01-24

Last Posted Date: 2023-09-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT05203380

Locations: 🇺🇸
DermAssociates, LLC, Rockville, Maryland, United States
🇺🇸
Clinical Research Center of Alabama, LLC, Birmingham, Alabama, United States
🇺🇸
Pediatric Skin Research, LLC, Coral Gables, Florida, United States

and more 7 locations

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

Phase 1

Completed

Conditions: Chronic Stable Illness
Healthy

Interventions: Drug: Casirivimab+Imdevimab

First Posted Date: 2022-01-06

Last Posted Date: 2022-06-21

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT05181683

Locations: 🇺🇸
Regeneron StudySite, Winter Park, Florida, United States
🇺🇸
Regeneron Study Site, Miami, Florida, United States

Home Terms & Conditions Privacy Policy